Introduction: Asymptomatic hyperuricemia (AHU) is a metabolic complication that worsens cardiovascular morbidity and mortality, particularly in type 2 diabetic patients (T2DM). Our study aimed to determine the prevalence and identify the determinants of AHU in type 2 diabetic patients in the Northern region of Cameroon. Methodology: This was a cross-sectional and analytic study conducted over two years, from May 1st, 2023, to April 30th, 2025, focused on type 2 diabetic patients at the diabetic outpatient consultation unit of the Garoua General Hospital (GGH). We included all T2DM patient files with uric acid measurements during the study period. We excluded incomplete files, patients with gout, and those with symptoms of acute gout flares. The logistic regression model revealed the determinants of AHU with a significance threshold of 5%. Results: Of the 210 patients included, with a median age of 52 (IQR: 43 - 62) years, 58.57% were men. The median duration of T2DM was 5 (IQR: 2 - 9) years, with 85.78% having poor glycemic control (A1c > 7%). The prevalence (95% CI) of AHU in our study population was 40.48 (33.82 - 47.45)%. The identified determinants [aOR (95% CI), p] to AHU were a past history of obesity [1.99 (1.03 - 3.83), p = 0.040] and a glomerular filtration rate <60 mL/mn/1.73m2 [5.95 (1.51 - 23.38), p = 0.011]. Conclusion: The high prevalence of AHU and its determinants (obesity and GFR < 60 mL/mn/1.73m2) require systematic screening and management to reduce cardiovascular risk.
References
[1]
Collège des hautes études en médecine (2025) La conduite à tenir devant une hyperuricémie asymptomatique. https://www.chem-sante.fr/newsletter_la-conduite-a-tenir-devant-une-hyperuricemie-asymptomatique/
[2]
Pascart, T., Latourte, A., Chalès, G., Coblentz-Baumann, L., Cohen-Solal, A., Ea, H., et al. (2020) Recommandations de la Société française de rhumatologie pour la prise en charge de la goutte: le traitement hypo-uricémiant. Revue du Rhumatisme, 87, 332-341. https://doi.org/10.1016/j.rhum.2020.07.009 https://www.sciencedirect.com/science/article/pii/S1169833020301514
[3]
Hakoda, M. and Kasagi, F. (2018) Increasing Trend of Asymptomatic Hyperuricemia under Treatment with Urate-Lowering Drugs in Japan. Modern Rheumatology, 29, 880-884. https://doi.org/10.1080/14397595.2018.1519149
[4]
Li, Q., Li, X., Wang, J., Liu, H., Kwong, J.S., Chen, H., et al. (2019) Diagnosis and Treatment for Hyperuricemia and Gout: A Systematic Review of Clinical Practice Guidelines and Consensus Statements. BMJ Open, 9, e026677. https://doi.org/10.1136/bmjopen-2018-026677 https://bmjopen.bmj.com/content/9/8/e026677?utm_content=consumer&utm_medium=cpc&utm_source=trendmd&utm_campaign=bmjo&utm_term=usage-042019
Johnson, R.J., Lanaspa, M.A. and Gaucher, E.A. (2011) Uric Acid: A Danger Signal from the RNA World That May Have a Role in the Epidemic of Obesity, Metabolic Syndrome, and Cardiorenal Disease: Evolutionary Considerations. Seminars in Nephrology, 31, 394-399. https://doi.org/10.1016/j.semnephrol.2011.08.002
[7]
(2025) Dictionnaire médical de l’Académie de Médecine. https://www.academie-medecine.fr/le-dictionnaire/index.php?q=ob%C3%A9sit%C3%A9%20andro%C3%AFde
[8]
(2025) Obésité et surpoids. https://www.who.int/fr/news-room/fact-sheets/detail/obesity-and-overweight
[9]
Masson, E. (2025) P024 Prévalence et facteurs prédictifs de l’hyperuricémie dans une popu-lation de patients diabétiques de type 2 camerounais. EM-Consulte. https://www.em-consulte.com/article/967765/p024-prevalence-et-facteurs-predictifs-de-l-hyperu
[10]
Kone, F., Touré, K.H., Kouassi, L., Acho, J.K., Yapa, G.S.K., Nzonzy, B.S.R., et al. (2025) Prevalence and Determinants of Hyperuricemia in Type 2 Diabetes Mellitus Patients in Bouaké. Prévalence et déterminants de l’hyperuricémie chez le patient diabétique de type 2 à bouaké. Health Research in Africa, 2, 64-68. http://hsd-fmsb.org/index.php/hra/article/view/5657
[11]
Wanvoegbe, F.A., Agbodande, K.A., Alassani, A., Gninkoun, J., Kerekou, A., Azon-Kouanou, A., et al. (2017) Hyperuricémie chez les diabétiques de type 2 à Cotonou: prévalence et facteurs associés. Journal de la Société de Biologie Clinique du Bénin, 27, 5-9. https://search.bvsalud.org/aimafro/resource/pt/biblio-1264147
[12]
Li, C., Hsieh, M. and Chang, S. (2013) Metabolic Syndrome, Diabetes, and Hyperuricemia. Current Opinion in Rheumatology, 25, 210-216. https://doi.org/10.1097/bor.0b013e32835d951e
[13]
Aksas, K. and Makrelouf, M. (2024). Hyperuricémies chez les diabétiques de type 2 et Conséquences métaboliques. Algerian Journal of Medical and Health Research, 2, 63-83. https://ajmhr.net/wp-content/uploads/2024/08/num%C2%ACro-9-63-83.pdf
[14]
Abate, N., Chandalia, M., Cabo-Chan, A.V., Moe, O.W. and Sakhaee, K. (2004) The Metabolic Syndrome and Uric Acid Nephrolithiasis: Novel Features of Renal Manifestation of Insulin Resistance. Kidney International, 65, 386-392. https://doi.org/10.1111/j.1523-1755.2004.00386.x
[15]
Daudon, M., Traxer, O., Conort, P., Lacour, B. and Jungers, P. (2006) Type 2 Diabetes Increases the Risk for Uric Acid Stones. Journal of the American Society of Nephrology, 17, 2026-2033. https://doi.org/10.1681/asn.2006030262
[16]
Shin, D.H. (2019) To Treat or Not to Treat Asymptomatic Hyperuricemia in Chronic Kidney Disease. Kidney Research and Clinical Practice, 38, 257-259. https://doi.org/10.23876/j.krcp.19.074 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727889/
[17]
EM Consulte (2025) Que faire devant une hyperuricémie asymptomatique? https://www.em-consulte.com/article/1269755/que-faire-devant-une-hyperuricemie-asymptomatique%C2%A0
